Final Data From Phase 2 Study Confirm High Response Rate Of Micromet’s Blinatumomab In Patients With Acute Lymphoblastic Leukemia

Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, announced data from its completed phase 2 clinical trial with blinatumomab in patients with B-precursor acute lymphoblastic leukemia (ALL). The data were presented in an oral presentation(1) at the 51st Annual Meeting of the American Society of Hematology (ASH) and were selected by the Society for inclusion in its “Best of ASH” session…

Go to Source

People who read this also read

• Data From Phase 1 Study Confirm High Response Rate Of Micromet’s Blinatumomab In Patients With Non Hodgkins Lymphoma
  Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, announced the publication of a poster(1) with new data from its ongoing phase 1 clinical trial of its product candidate blinatumomab ...
• New Data From Phase III Lung Cancer Trial Show VeriStrat(R) Identifies Patients Likely To Respond To Erlotinib
  Results from the VeriStrat biomarker analysis of a multicenter Phase III trial were presented at the 2nd European Lung Cancer Conference currently being held in Geneva, Switzerland. Results showed that the VeriStrat test identified patients who were likely to have a survival benefit from treatment ...
• Sunesis Poised For Phase 3 Trial Of Voreloxin In Acute Myeloid Leukemia After Completing Formal End-of-Phase 2 Meetings With FDA
  Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) announced that it has completed formal End-of-Phase 2 meetings with the U.S. Food and Drug Administration (FDA) related to its lead compound, voreloxin, in acute myeloid leukemia (AML). Sunesis has received feedback and guidance from the FDA in response t...
• Positive Phase IIb Topline Clinical Data For Celgene Oral Compound Apremilast (CC-10004) Reported For Patients With Moderate-to-Severe Psoriasis
  Celgene Corporation (NASDAQ:CELG) announced clinical data from an investigational Phase IIb, double-blind, placebo-controlled study of apremilast (CC-10004) in patients with moderate-to-severe plaque-type psoriasis (PSOR-005). This was a 352-patient, multi-center study in which patients received eit...
• Ambit Biosciences Initiates First Phase 2 Clinical Trial Of AC220 In Acute Myeloid Leukemia
  Ambit Biosciences Corporation announced the enrollment and dosing at the University of Texas M. D. Anderson Cancer Center of the first patient in the ACE (AC220 Monotherapy Efficacy) Phase 2 pivotal trial in patients with relapsed or refractory acute myeloid leukemia (AML). AC220 is a novel, orally ...